Springer Nature AG & Co. KGaA (SPGNY)
Technology · OTC Markets OTCPK · US
Fundamentals
Valuation and ratings
Springer Nature AG & Co. KGaA trades at USD10.54. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Springer Nature AG & Co. KGaA
Springer Nature AG & Co. KGaA, together with its subsidiaries, engages in the publishing business in Germany, the United Kingdom, the United States, and internationally. The company operates through three segments: Research, Education, and Health. It offers journals across various academic disciplines under the Nature Portfolio and Springer brand names; books in print and digital formats across various scientific disciplines, including monographs, textbooks, conference proceedings, handbook series, reference works, and briefs under the Springer and Palgrave Macmillan brand names; and support services to researchers, institutions, and industry professionals with AI-powered tools and services, such as AdisInsight, Springer Nature Experiments, protocols.io, and SpringerMaterials, as well as professional development and career services under the Nature Masterclasses, Nature Careers, and Nature Conferences brand names. The company also provides English language teaching content and national curricula learning resources under the Macmillan Education brand name. In addition, it offers specialist information and services to healthcare professionals under the Springer Medizin brand name; publications, learning solutions, and professional services to healthcare practitioners and students under the BSL brand name; content and services related to drug treatments, medical devices, and diagnostics under the Springer Health+ brand name; and Cureus Journal of Medical Science, a peer-reviewed OA medical journal. The company was founded in 1842 and is based in Berlin, Germany. Springer Nature AG & Co. KGaA operates as a subsidiary of GvH Vermögensverwaltungsgesellschaft Xxxiii mbH.
SPGNY passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
The full research page for SPGNY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.